LIA
PCVX icon

Limestone Investment Advisors’s Vaxcyte PCVX Stock Holding History

Limestone Investment Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9,600
Closed -$346K – 608
2025
Q3 		$346K Buy
+9,600
New +$318K 0.03% 317

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Limestone Investment Advisors's PCVX Position: Q4 2025 in Review

Limestone Investment Advisors sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 9,600 shares — an estimated $346K sold.

Limestone Investment Advisors first reported a position in PCVX in Q3 2025 and held it in 1 quarter. The position peaked at $346K in Q3 2025. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

  • Limestone Investment Advisors reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
  • Limestone Investment Advisors sold 9,600 Vaxcyte shares in Q4 2025, an estimated $346K.
  • Limestone Investment Advisors first reported a position in Vaxcyte in Q3 2025 and held it in 1 quarter.
  • Limestone Investment Advisors's Vaxcyte position peaked at $346K in Q3 2025.
  • 295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Limestone Investment Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.